No massive reverse split. GC has stated many times the company will not do that, and uplist will be pushed further out if market conditions are not right.

Everyone needs to get out of the expectation of an uplist based on a stated timeline. No one knows how the market will respond to upcoming milestones being met (including GC), but I'm confident once LymPro revenue generation starts, or we see up-front partnership money, the share price will respond accordingly.

The uplist happens when the time is right, not according to expectations. I don't believe for a second the company will do a massive RS just to get off of OTC.

This is a great time to be invested in the company. Our long wait is nearing an end.